Company / Operating Cash Flow
Neurocrine Biosciences Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$782.7M
FY2025
5-year range
$256.5M / $782.7M
FY2021-FY2025
Trend
+31.5%
vs FY2024
Sector context
#24 of 214
Health Care
What the data says
Neurocrine Biosciences's operating cash flow of $783M is higher than 89% of companies in the Health Care sector (FY2025). Operating Cash Flow has increased for 9 consecutive years, from -$106M in FY2016 to $783M in FY2025.
Based on SEC 10-K filings.
$783M in FY2025 with a 5-year CAGR of +27.9%. Top quartile in the Health Care sector.
Improved from $390M to $783M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- +32.1%
- 5-Year CAGR
- +27.9%
- 10-Year CAGR
- -
Sector benchmark
+18.0% above sector average
Key checks
Key Insights
- Neurocrine Biosciences's operating cash flow has grown for 9 consecutive years.
- 5-year CAGR of +27.9%, indicating consistent growth.
- In FY2025, operating cash flow increased 31.5% year-over-year.
- Ranks #24 out of 214 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $782.7M | +31.5% |
| FY2024 | $595.4M | +52.7% |
| FY2023 | $389.9M | +14.9% |
| FY2022 | $339.4M | +32.3% |
| FY2021 | $256.5M | +12.3% |
| FY2020 | $228.5M | +55.4% |
| FY2019 | $147.0M | +45.0% |
| FY2018 | $101.4M | +207.5% |
| FY2017 | -$94.3M | +11.2% |
| FY2016 | -$106.2M | -179.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026